PF-07258669

• CAT Number: I042623
• CAS Number: 2755890-53-8
• Molecular Formula: C25H27FN6O2
• Molecular Weight: 462.52
• Purity: ≥95%
• Synonyms: (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-pyrimidin-2-ylspiro[3,4-dihydro-1H-1,8-naphthyridine-2,3′-pyrrolidine]-1′-yl]propan-1-one
• IUPAC Name: (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-pyrimidin-2-ylspiro[3,4-dihydro-1H-1,8-naphthyridine-2,3'-pyrrolidine]-1'-yl]propan-1-one
• InChI: InChI=1S/C25H27FN6O2/c1-15(18-12-21(34-3)29-13-20(18)26)24(33)32-10-7-25(14-32)6-5-17-11-19(16(2)30-22(17)31-25)23-27-8-4-9-28-23/h4,8-9,11-13,15H,5-7,10,14H2,1-3H3,(H,30,31)/t15-,25+/m1/s1
• InChIKey: PARGFYLSRQUWHR-BZQUYTCOSA-N
• SMILES: CC1=C(C=C2CC[C@@]3(CCN(C3)C(=O)[C@H](C)C4=CC(=NC=C4F)OC)NC2=N1)C5=NC=CC=N5

​PF-07258669（Cat No.:I042623）is a potent and selective melanocortin-4 receptor (MC4R) antagonist developed by Pfizer. MC4R is a G protein-coupled receptor primarily expressed in the hypothalamus, playing a crucial role in regulating appetite and energy balance. Inhibition of MC4R signaling has been associated with increased food intake and weight gain, suggesting therapeutic potential for conditions like cachexia and anorexia. PF-07258669 has demonstrated significant efficacy in preclinical models, such as aged rat cachexia models. As of early 2025, it has undergone Phase I clinical trials in the United States and Belgium to evaluate its safety, tolerability, and pharmacokinetics in healthy adult participants.